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Levothyroxine replacement treatment in hypothyroidism is unable to restore physiological
thyroxine and triiodothyronine concentrations in serum and tissues completely. Normal
serum thyroid stimulating hormone (TSH) concentrations reflect only pituitary euthyroidism
and, therefore, novel biomarkers representing tissue-specific thyroid state are needed.
MicroRNAs (miRNAs), small non-coding regulatory RNAs, exhibit tissue-specific expression
patterns and can be detectable in serum. Previous studies have demonstrated differential
expression of (precursors of) miRNAs in tissues under the influence of thyroid hormone.
Objective
To study if serum miRNA profiles are changed in different thyroid states.
Design and methods
We studied 13 athyroid patients (6 males) during TSH suppressive therapy and after 4
weeks of thyroid hormone withdrawal. A magnetic bead capture system was used to isolate
384 defined miRNAs from serum. Subsequently, the TaqMan Array Card 3.0 platform was
used for profiling after individual target amplification.
Results
Mean age of the subjects was 44.0 years (range 20–61 years). Median TSH levels were
88.9 mU/l during levothyroxine withdrawal and 0.006 mU/l during LT4 treatment with a
median dosage of 2.1 μg/kg. After normalization to allow inter-sample analysis, a paired
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analysis did not demonstrate a significant difference in expression of any of the 384 miRNAs
analyzed on and off LT4 treatment.
Conclusion
Although we previously showed an up-regulation of pri-miRNAs 133b and 206 in hypothy-
roid state in skeletal muscle, the present study does not supply evidence that thyroid state
also affects serum miRNAs in humans.
Introduction
Hypothyroidism is one of the most common endocrine disorders [1]. In a subset (~10–15%)
of patients, symptoms of hypothyroidism persist despite serum thyroid hormone concentra-
tions within the laboratory reference range during levothyroxine (LT4) replacement therapy
[2–4]. One of the explanations for this impaired well-being might be the inadequacy of LT4
treatment to restore physiological thyroxine (T4) and triiodothyronine (T3) concentrations,
especially the T4/T3 ratio, in serum and tissues [5, 6]. Studies in hypothyroid rats showed that
LT4 monotherapy was unable to normalize concentrations of T4 and T3 in all tissues [7].
Supra-physiological serum T4 concentrations had to be reached in most tissues to normalize
tissue T3 concentrations and the LT4 dose required to normalize thyroid hormone concentra-
tions was different for each tissue.
Serum TSH concentrations, reflecting the pituitary feedback to thyroid hormone, is used in
clinical practice to monitor LT4 treatment because it is the best available marker of thyroid
state. However, although TSH typically reflects local T3 concentrations in the pituitary, it may
not necessarily reflect local thyroid status in all tissues, especially when thyroid hormone pro-
duction is not endogenously controlled, such as in athyreotic patients during LT4 therapy [8,
9]. For this reason, novel markers representing thyroid state of other tissues than the pituitary
would be of great clinical relevance.
MicroRNAs (miRNAs) are non-coding RNA molecules with a length of approximately 22
nucleotides, which predominantly post-transcriptionally repress the translation of mRNAs
from target genes by binding to the 3’UTR of messenger RNA [10–12]. Overall, miRNAs
exhibit tissue-specific expression patterns and each miRNA may affect the expression of hun-
dreds of target genes. Recently, we reported on gene expression profiles in skeletal muscle of
hypothyroid patients off and on LT4 therapy and found a large up-regulation in expression of
the muscle-specific pri-miRNAs 133b and 206 in hypothyroid state [13]. This was supported
by other studies that found an increase in expression of miRNAs- 1, 206, 133a and 133b in liv-
ers of hypothyroid mice compared to euthyroid controls [14]. MiRNAs can also be present in
the circulation and have been associated with a variety of diseases [15, 16]. We therefore
hypothesized that miRNA profiles in serum can also be influenced by thyroid state, and that




Patients with differentiated thyroid cancer (DTC) are exposed to different thyroid states as
part of their treatment. These patients are subject to severe hypothyroidism before radioactive
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iodine (RAI) therapy to stimulate radioactive iodine uptake by malignant tissues, whereas they
have relatively high thyroid hormone concentrations afterwards when receiving substitution
therapy with LT4 to suppress TSH. As a consequence, these patients are an ideal model to
study the consequences of different thyroid states longitudinally. Therefore, we used patients
with DTC as a model to quantify serum levels of 384 miRNAs in different thyroid states. Since
we were previously able to detect significant changes in numerous gene transcripts in periph-
eral blood as well as in muscle samples in respectively 8 and 10 patients, while using a similar
study design, we postulated that 13 patients would be enough to identify clinically relevant
markers [13, 17]. Using alpha = 0.05 and power = 80%, we would be able to detect a Cohen’s d
effect size of 0.87, which is considered as a large effect.
13 DTC patients were consecutively recruited from the outpatient clinic of the Erasmus
Medical Center, between May 1st 2013 and February 1st 2015. Patients were eligible for inclu-
sion if they needed RAI therapy during LT4 withdrawal according to the Dutch guidelines
[18], had no other malignancies or an active inflammatory disease, and were between 18 and
80 years old.
The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical
Center (MEC 2012–561) and written informed consent was obtained from all study
participants.
Thyroid function measurements
Peripheral blood samples were obtained in non-fasting conditions from all participants on and
off LT4 treatment. Serum Free T4 (FT4, reference range 11–25 pmol/L) and total T3 (reference
range 1.4–2.5 nmol/L) concentrations were measured by chemoluminescence assays (Vitros
ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, Rochester, MI). Serum TSH con-
centration (reference range 0.4–4.3 mU/L) was determined by immunometric assay (Immulite
2000 XPi, Siemens, Den Haag, the Netherlands). Serum samples were stored at −80 ˚C until
further analysis of miRNAs.
miRNA isolation from serum
The method of miRNA isolation and quantification has been previously described extensively
[19]. In short, the miRNAs were purified from serum samples using TaqMan ABC Purification
Kit—Human Panel A (Thermo Fisher, PN 4473087). These panels consist of superparamag-
netic Dynabeads covalently bound to a unique set of 384 anti-miRNA oligonucleotides. The
miRNAs match the miRNAs in Megaplex Pool described below. The panel includes exogenous
and endogenous controls. Briefly, 100 μL of lysis buffer was added to 50 μL of serum. One μL
of 1 nM of a non-human external control (ath-miRNA-159a) was added to monitor the extrac-
tion process, followed by the addition of 80 μL of beads (80 × 106 beads). The tubes were
mixed for 40 min at 1200 rpm and 30 ˚C, the beads were isolated using a magnetic bead sepa-
rator, and washed three times with wash buffer. The bound miRNAs were eluted from the
beads with 100 μL elution buffer and incubated at 70 ˚C for 3 min. The eluted miRNA pool
was stored at −80 ˚C until ready to use.
For miRNA profiling, Megaplex Primer Pool A was used in conjunction with the matching
TaqMan miRNA Array Card A. All reagents were purchased from Thermo Fisher/Life Tech-
nologies (Bleiswijk, NL). Briefly, 3 μL of the miRNA sample isolated with the ABC kit was
reverse transcribed with the Megaplex RT Primer Pool A (PN 4399966) in a 8 μL final volume.
The RT reaction was performed under thermal cycling (2 min at 16 ˚C, 1 min at 42 ˚C, 1 sec at
50 ˚C, for 40 cycles) and the enzyme was inactivated by treatment for 5 min at 85 ˚C. Four μL
RT reaction was combined with its matching Megaplex PreAmp Primer Pool (PN 4399233)
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and TaqMan PreAmp Master Mix (PN 4391128) in a final volume of 25 μL. Pre-amplification
was done using the following cycling conditions: 10 min at 95 ˚C; 2 min at 55 ˚C; 2 min at
72 ˚C; 15 sec at 95 ˚C, 4 min at 60 ˚C for 12 cycles; 99 ˚C for 10 min. The final pre-amplifica-
tion product was diluted 1:100 in 1X TaqMan Universal Master Mix (PN 4364341), then
loaded onto the matching TaqMan MiRNA Array Card A (PN 4398965) and run on a Taq-
Man1 7900HT Fast Real-Time PCR System under universal cycling conditions.
miRNA quantification
Raw data files were imported and analyzed using ExpressionSuite v1.0.4 (Life Technologies,
South San Francisco, CA, USA), a software data analysis tool that can easily import and ana-
lyze large raw data files. In these experiments, the quantification cycle (Cq) is defined as the
fractional cycle at which the amplification plot crosses the fluorescence threshold (Ct). The
baseline was set automatically and the threshold was manually set at 0.2 and adjusted whenever
appropriate to get an intersection in the exponential part of the curve. To capture as many dif-
ferentially expressed miRNAs as possible, the threshold was set at 40 instead of 30–32 which is
generally recommended by Life Technologies for relatively high miRNA levels. Undetermined
values were replaced with the maximal number of cycles (= 40) [20]. The non-human external
control (ath-miRNA 159a) differed between the serum samples with Cq values ranging
between 23.0 and 26.9 (mean Cq value 24.4; SD 0.96). In previous studies using the same pro-
tocol, variation in spike-in controls has been reported to be similar [21].
TaqMan miRNA array output data (sds files) were uploaded in the ThermoFisher Cloud
App (https://www.thermofisher.com/mysso/loginDisplay) and analyzed using defined thresh-
old settings for each individual miRNA. Cq values were exported and filtered for poor amplifi-
cation performance (Amplification Status, Amp Score and Cq Conf, Supplementary S1 Table).
MiRNAs with average Cq values below 37 were included for statistical analysis. In addition,
miRNAs were selected which had Cq values <37 in all samples, representing abundant
miRNAs.
Software and statistics
In order to correct for differences in input, global normalization was performed (Supple-
mentary S1 Table) using QbasePlus (Biogazelle N.V., Zwijnaarde, Belgium) according to
Mestdagh et al. [22]. A second method for normalization, also using endogenous controls,
was performed. Based on an established algorithm for stability analysis (Normfinder),
miRNA 93 and miRNA 130a turned out to be the most stable combination of miRNAs with
mean Cq values (±SD) of 28.3 (±0.58) and 30.5 (±0.6) respectively [23](23). Normalization
was also performed using the mean of these normalizers. Heatmaps of miRNA data were
generated in R using the “pheatmap” clustering software package using the default settings.
The Wilcoxon signed rank test was used for paired comparison of miRNA levels (ΔCq) and
thyroid function tests on and off LT4 treatment. Multiple comparison adjustment was
applied using the FDR approach [24].
Results
Characteristics of 13 study patients are shown in Table 1. Mean age was 44.0 years (±SD 11.1)
and mean BMI was 30.0 kg/m2 (±SD 6.0). Three of the patients (subjects 11–13) were treated
with remnant ablation RAI therapy 4 weeks after thyroidectomy while the others were pre-
pared for an extra RAI treatment by thyroid hormone withdrawal because of (suspicion of)
residual or recurrent disease or positive anti-thyroglobulin (anti-Tg) antibodies.
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As expected, thyroid function tests were significantly different on and off LT4 treatment
(Table 2), reaching low levels of total T3 and FT4 with elevated TSH levels off LT4
replacement.
Profiling of miRNAs
Out of the 384 miRNAs analyzed, almost half showed very low to undetectable levels. After
removing all miRNAs with average Cq values > 37, only 135 miRNAs remained for analysis
(S1 Table). Clustering of these globally normalized miRNAs did not group the samples accord-
ing their thyroid state (Fig 1). The clustering of the abundant miRNAs (Cq values<37 in all
samples, n = 59) did not separate the samples according their thyroid state as well (S1 Fig).
After calibration and normalization on the global mean, the statistical analysis revealed that
none of the miRNAs was significantly altered between different thyroid states after correction
for multiple testing (S1 Table). As a complementary approach, we normalized the dataset on
the mean levels of two endogenous reference miRNAs (miRNA 93 and miRNA 130a). This
confirmed the absence of any significant differences in levels of any of the miRNAs analyzed
between thyroid states (S1 Table).
Previously reported miRNAs. The profiles of miRNAs which have been previously
reported to be differentially expressed in muscle and liver in hypothyroidism were evaluated
Table 1. Baseline characteristics.
Subject Age (years) Sex BMI (kg/m2) Type of tumor Comorbidity Number of RAI treatments Tg-off (μg/l) Post-therapy I131 scan
1 49 Male 25.8 PTC Pulmonary embolism 1 3.9 No uptake
2 51 Female 34.1 PTC none 1 2.1 No uptake
3 34 Male 36.4 PTC none 4 517.0 Sacral metastasis
4 47 Female 32.9 PTC hypoparathyroidism 1 94.4 No uptake
5 50 Male 24.5 PTC none 3 5.6 LN
6 20 Female 20.7 PTC hypoparathyroidism 1 <0.9 No uptake
7 37 Female 24.6 PTC none 2 21.8 Mediastinal LN
8 39 Male 40.5 PTC none 3 12.9 No uptake
9 58 Female 29.0 FTC none 1 <0.9 Not performed
10 61 Female 26.7 PTC hypertension 1 21.6 No uptake
11 48 Female 35.1 PTC hypertension 0 <0.9 Thyroid remnant
12 45 Male 34.9 PTC hypertension 0 7.5 Thyroid remnant
13 33 Male 25.0 PTC none 0 <0.9 Thyroid remnant
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; BMI, body mass index; RAI, radioactive iodine; Tg, thyroglobulin; LN, lymph node.
anti-Tg positive
https://doi.org/10.1371/journal.pone.0194259.t001
Table 2. Thyroid function tests.
Off LT4 On LT4 P
TSH (0.4–4.3 mU/l) 88.9 (56.5–118.5) 0.006 (0.004–0.015) 0.001
Total T3 (1.4–2.5 nmol/l) 0.64 (0.58–0.70) 2.13 (2.0–2.3) 0.001
Free T4 (11.0–25.0 pmol/l) 1.6 (0.4–1.8) 25.7 (22.4–29.3) 0.001
Dosage LT4 (μg/kg) 2.1 (1.9–2.6)
Time between tests, weeks (range) 24.7 (11.0–38.8)
Changes in thyroid function tests (normal range) off and on LT4 treatment. Data are presented as median with interquartile range. LT4, levothyroxine; TSH, thyroid
stimulating hormone; T3, triiodothyronine.
https://doi.org/10.1371/journal.pone.0194259.t002
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Fig 1. Heat map showing the Cq values of all detectable MiRNAs (n = 135) in the different thyroid states. Clustering did not group the samples
according to thyroid state.
https://doi.org/10.1371/journal.pone.0194259.g001
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[13, 14]. The level of miRNA 1 and miRNA 133b were not amongst the 135 detectable miRNAs
(S1 Table). MiRNA 206 was not on the card. MiRNA 133a showed a mean Cq value of 31.2
(±1.2) in hypothyroid state versus 31.3 (±1.7) in hyperthyroid state (not significantly
different).
Discussion
To our knowledge, this is the first study investigating a selected multi-target miRNA profile in
serum of individual patients during (extreme) changes in thyroid states. Most studies on miR-
NAs in patients with thyroid disease have focused on thyroid cancer [25]. A study by Yamada
et al, reported several miRNA levels that were differently expressed in serum from patients
with autoimmune thyroid disease compared with healthy subjects [26]. They suggested that
the underlying autoimmune condition was responsible for the observed changes since there
was no association between the mentioned miRNAs and TSH levels. However they did not
study the changes in miRNA expression after restoring euthyroidism [26]. Another study
demonstrated that different levels of circulating miRNAs are associated with intractable
Graves’ disease compared with Graves’ disease in remission [27].
In our study, we could not find significant changes in levels of serum miRNAs in athyroid
hypothyroid patients on and off LT4 treatment, despite previous studies showing clear differ-
ences in (precursors of) miRNAs in different tissues [13, 14, 28]. There are a number of possi-
ble explanations for our results. First, our sample size might have been too small to discover
significant changes in miRNA levels. However, previously, in a cohort of similar size, microar-
ray analysis revealed large differences between thyroid states in muscle samples, suggesting
that the used sample size was sufficient if the differences would have been equally large and
consistent [13]. McDonald et al. found that assay imprecision (due to variability in the RNA
extraction process and interassay imprecision) had significant effects on the reproducibility of
miRNA measurements and concluded that only miRNAs that are extremely up- or downregu-
lated will be suitable as clinical biomarkers [29]. If there were such extremely up- or downre-
gulated miRNAs they should have been detected in our sample size. Second, although it has
been shown that miRNAs are present in human plasma and serum in a remarkably stable
form that is protected from endogenous RNase activity [15], differences in the time between
blood drawing and storage potentially impact on the miRNA levels released from blood cells,
in particular if samples are stored over 24h [29]. However, all our samples were stored at -80
˚C within 2 to 4 hours of collection and therefore a significant effect on miRNA expression is
not likely [30]. Third, although after calibration, normalization of the data was performed
using two different methods (based on the global mean and based on mean levels of two
endogenous reference miRNAs) providing similar results, we cannot rule out that a variation
in protocol efficiency might have influenced our results. Finally, although several studies have
shown that thyroid hormones seem to regulate miRNA expression in several organs such as
skeletal muscle, liver and heart, these changes in tissue miRNA expression may not be reflected
in serum [13, 14, 28]. It has to be mentioned that our previous study in muscle samples exam-
ined only precursors of mature miRNAs (pri-miRNAs) while our current study investigated
the effects of TH on the levels of mature miRNAs. However, Dong et al. found significant
decreases of both mature miRNAs and it’s corresponding precursor miRNAs in liver samples
of hypothyroid mice compared to euthyroid controls [14].
Our study has several strengths and limitations. A limitation of our study is that we only
studied a selection of 384 miRNAs and we cannot rule out that other miRNAs, which were not
included in our platform are influenced by thyroid state. For example, miRNA 206, of which
the precursor pri-miRNA-206 differed significantly in skeletal muscle, was not included in the
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current platform. A possible confounder of our study is that we studied patients with DTC,
while several miRNAs in serum have been postulated as biomarker for DTC [25]. The levels of
serum let-7e, miRNA-151-5p, microRNA-146b and miRNA-222 have been reported to be sig-
nificantly increased in PTC patients relative to healthy controls [31, 32]. Circulating levels of
miRNA-146a-5p, miRNA-146b-5p, miRNA-221-3p, and miRNA-222-3p have been shown to
decline after tumor excision [33]. Although seven of our patients did not show any uptake on
the post-therapy RAI scan and Tg-off levels were mostly low, some miRNAs theoretically
could have been changed by the response of the tumor to RAI therapy or to the radiation it
selves. Finally, although all patients with active inflammatory disease or other malignancies
were excluded, some patients had comorbidities which might have affected their T3-depen-
dent miRNA profile. Our study has several strengths as well. First, the study design included
paired analyses, which has the advantage to reduce confounders. Second, we were able to
study extreme differences in thyroid state in human subjects. Finally, we used a validated and
widely used method to generate the serum miRNA profile [20, 34–36].
In conclusion, although we previously showed regulation of pri-miRNAs by thyroid hor-
mone in muscle samples, the present study using an extensive panel of 384 miRNAs does not
supply evidence of regulation of mature miRNAs in serum by thyroid hormone.
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S1 Table. Raw data and results of the statistical analysis with normalization on the global
mean.
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S1 Fig. Heat map showing the Cq values of the abundant miRNAs (Cq values <37 in all
samples, n = 59) in the different thyroid states. Clustering did not group the samples accord-
ing to thyroid state.
(PDF)
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